ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Is Coconut Oil Healthy? (The American Heart Association Doesn’t Think So)

American Heart Association Renders Itself Obsolete With 1960s Dietary Advice on Coconut Oil

Ginger Fights Obesity

Health Benefits of Artichokes

Putting the Spotlight on Coriander Seed Oil

Migraines? Powdered Ginger May Help

Are Americans Really Getting Too Much Vitamin D? A Critical Look at Recent Media Warnings

Eating more vegetable protein may protect against early menopause

Vitamin C and antibiotics: A new one-two 'punch' for knocking-out cancer stem cells

German Chamomile Oil: A Versatile Essential Oil You Should Have at Home

 
Print Page
Email Article

$13 million grant puts new herpes-based AIDS vaccine on fast track

  [ 18 votes ]   [ Discuss This Article ]
www.ProHealth.com • August 1, 2003


In an unlikely twist in the fight against AIDS, scientists have re-engineered a herpes virus – stripping most of its DNA and replacing it with small snippets of DNA from the AIDS virus – in a bid to create a new type of AIDS vaccine.

Early tests in mice suggest that the new vaccine could help the immune system make more infection-fighting antibodies and killer T-cells than other vaccines, which could make it more effective. The University of Rochester researchers who have pioneered the new approach have been awarded a $13 million grant from the National Institutes of Health to complete the additional testing necessary to move the vaccine into clinical trials.

"We've known for some time that the herpes virus is a very effective vehicle for delivering material into cells," said Howard Federoff, M.D., Ph.D., a University of Rochester scientist who has spent the last decade developing the new vaccine approach. "We've recently been able to harness one of the virus' most useful features, giving us a new tool that appears to have strong potential as an AIDS vaccine."

That feature is a string of DNA, called an amplicon, that causes the virus' DNA to be copied many times over before the virus infects a healthy cell. When Federoff and his colleagues re-engineered the herpes virus for use as a vaccine, they removed most of the herpes DNA and replaced it with snippets of DNA from the AIDS virus. That DNA provided the instructions for making key protein molecules that are found in the AIDS virus.

When the re-engineered herpes virus was injected into mice, healthy cells in the mouse began making those proteins. The immune system, in turn – recognizing the proteins as foreign – began producing antibodies and killer T-cells to attack and destroy them. Should an HIV infection strike, the researchers hope that those antibodies and killer T-cells would mount an aggressive attack against the infection before it can take hold and cause AIDS.

Other potential AIDS vaccines have used a similar approach, but most produced just small quantities of the desired proteins from the AIDS virus. By using the herpes virus – and by harnessing the DNA-copying ability of its amplicon – the researchers have engineered the virus to deliver many times the DNA of earlier vaccines. In their prototype AIDS vaccine, the researchers have packaged enough DNA to produce fragments of six different proteins from the AIDS virus. The amplicon then amplified those six DNA segments, producing 10 to 15 copies of each.

"Think of the virus as an envelope that delivers written pages," said Stephen Dewhurst, Ph.D., a virologist who serves as co-principal investigator for the project. "Most envelopes can deliver a few pages. This envelope can deliver a book."

Dewhurst and his colleagues believe that the large number of DNA segments will cause cells to produce a greater number of AIDS-virus protein fragments, and that the immune system will, in turn, produce a larger number of antibodies and killer T-cells. As a result, the immune system should be much better armed against a potential HIV infection.

At the same time, the vaccine is likely to be safe. No live virus is used, and all of the disease-causing genes from the herpes virus have been removed. The DNA segments from the AIDS virus have been carefully selected and have been proven not to cause AIDS.

The goal of the five-year, $13 million grant is to complete the early development of the vaccine and prepare it for the first tests in people. Michael Keefer, M.D., a vaccine researcher who specializes in clinical testing of AIDS vaccines, is the principal investigator on grant. He will coordinate a team of more than a dozen scientists working in two groups. One, led by Federoff, will work to fine tune the re-engineered herpes virus and the packaging of its DNA payload for use as a vaccine. William Bowers, Ph.D., a virologist and molecular biologist, will lead an effort to ensure that the vaccine can be "scaled up" – that is, manufactured in large quantities without quality problems that could diminish the vaccine's effectiveness or safety. A second group, led by Dewhurst, will test the vaccine in laboratory animals to assess its safety and effectiveness. In particular, they will try to determine how well the vaccine spurs the immune system to produce antibodies and killer T-cells and how long those effects last.

"Using the herpes virus amplicon is one of the most innovative approaches I've seen in the effort to develop an AIDS vaccine," said Keefer. "It's exciting to help move this technology forward and to see what its capabilities are. This is cutting-edge vaccine work that may prove useful against HIV as well as a range of other diseases."

Federoff's laboratory is also pursuing the development of amplicon vaccines for use against several types of cancer and neurological disorders such as Alzheimer's and Parkinson's disease.



Post a Comment

Featured Products From the ProHealth Store
FibroSleep™ Mitochondria Ignite™ with NT Factor® Ultra ATP+, Double Strength

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength

Natural Remedies

Carry a Massage Therapist in Your Pocket Carry a Massage Therapist in Your Pocket
Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery
Milk Thistle: Trusted Support for Health & Healing in a Toxic World Milk Thistle: Trusted Support for Health & Healing in a Toxic World
Breakthrough Form of Magnesium Enhances Memory and Cognitive Function Breakthrough Form of Magnesium Enhances Memory and Cognitive Function
Thyroid Health and Fibromyalgia Thyroid Health and Fibromyalgia

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map